Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 7/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22095066 | 0.78 | HTT (0.52) | GRM1ALOX15HTTNPC1RAB9A | |
| SCHEMBL22095171 | 0.77 | HTT (0.54) | ALOX15HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18369634 | 0.76 | HTT (0.52) | ALOX15HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2538454 | 0.76 | ALDH1A1 (0.47) | ALOX15HTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13536819 | 0.74 | GRM1 (0.61) | GRM1ALOX15HTTNPC1RAB9A | |
| SCHEMBL10627567 | 0.74 | TDP1 (0.66) | ALOX15HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22095112 | 0.73 | GRM1 (0.39) | GRM1HSD17B10 | |
| SCHEMBL31544141 | 0.73 | ALDH1A1 (0.51) | GRM1ALOX15HTTNPC1RAB9A | |
| SCHEMBL31419248 | 0.73 | GRM1 (0.51) | GRM1ALOX15HTTNPC1RAB9A | |
| SCHEMBL2315368 | 0.73 | CA1 (0.59) | ALOX15HTTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-06 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | GRM1 4114/4885ALOX15 2171/4885HTT 1786/4885 |
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | GRM1 4114/4885ALOX15 2171/4885HTT 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.